Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
NCT00525161
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class
Stopped
Slow accrual and loss of funding
Conditions
Breast Cancer
Interventions
DRUG:
sorafenib
Sponsor
Suleiman Massarweh
Collaborators
[object Object]